Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
14 results
D1.116 - Severe Airflow Limitation Unmasked by NSAID Hypersensitivity: A Case of Undiagnosed Persistent Asthma with Nasal Polyposis
D1.117 - Combing dual biologics therapy for severe asthma : a series of ten cases
D1.118 - The Use of Long-Acting Muscarinic Antagonist in the Treatment of Asthma: A Latin-American 2 Specialized Asthma Center Experience
D1.119 - Anti-Inflammatory Effects of miRNA-Mediated Extracellular Vesicles Derived from Mesenchymal Stem Cells in a Murine Asthma Model
D1.123 - Inhibition of the Interleukin Cytokines using novel Peptide Inhibitors for Allergy and Asthma Treatment
D1.124 - Predictive Factors of Clinical Remission in Severe Eosinophilic Asthma Treated with Benralizumab
D1.125 - Biological therapy in severe asthma: 20 years of experience at the Hospital Universitario de Burgos
D1.129 - Bispecific Antibody Targeting IL-33 and TSLP for Treating Asthma and COPD
D1.131 - TRough levels In plasma of dUpilumab and Mepolizumab in Patients with severe astHma (TRIUMPH)
D3.23 - Descriptive and Comparative Analysis of Clinical and Endoscopic Characteristics and Treatment Response in Adult Patients with Eosinophilic Esophagitis (EoE): a preliminary experience of an Italian centre
D3.26 - Anaphylaxis associated with biosimilar Tocilizumab: in vitro and in vivo diagnosis
D3.28 - Comparative Efficacy and Safety of Omalizumab Intended copy Biosimilar vs. Biologic in Chronic Spontaneous Urticaria
D3.29 - Detailed Clinical Characterization of a Large Cohort of Chronic Spontaneous Urticaria Patients
D3.33 - Severe Eosinophilic Esophagitis: the Key Role of Biologics in Disease Management
Download the app
The congress at your fingertips
Available on
Download